Selective anti-PD-L1, anti-PD-1, and/or anti-CTLA-4 mAbs have brought about a revolution in treatment of many types of cancer, among which lung cancer and melanoma have seen the greatest clinical efficacy. This evidence concerns the gene CTLA4 and cancer.